1
|
Navarro-Compán V, Boel A, Boonen A, Mease P, Landewé R, Kiltz U, Dougados M, Baraliakos X, Bautista-Molano W, Carlier H, Chiowchanwisawakit P, Dagfinrud H, de Peyrecave N, El-Zorkany B, Fallon L, Gaffney K, Garrido-Cumbrera M, Gensler LS, Haroon N, Kwan YH, Machado PM, Maksymowych WP, Poddubnyy D, Protopopov M, Ramiro S, Shea B, Song IH, van Weely S, van der Heijde D. The ASAS-OMERACT core domain set for axial spondyloarthritis. Semin Arthritis Rheum 2021; 51:1342-1349. [PMID: 34489113 DOI: 10.1016/j.semarthrit.2021.07.021] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Revised: 07/28/2021] [Accepted: 07/29/2021] [Indexed: 01/20/2023]
Abstract
BACKGROUND The current core outcome set for ankylosing spondylitis (AS) has had only minor adaptations since its development 20 years ago. Considering the significant advances in this field during the preceding decades, an update of this core set is necessary. OBJECTIVE To update the ASAS-OMERACT core outcome set for AS into the ASAS-OMERACT core outcome set for axial spondyloarthritis (axSpA). METHODS Following OMERACT and COMET guidelines, an international working group representing key stakeholders (patients, rheumatologists, health professionals, pharmaceutical industry and drug regulatory agency representatives) defined the core domain set for axSpA. The development process consisted of: i) Identifying candidate domains using a systematic literature review and qualitative studies; ii) Selection of the most relevant domains for different stakeholders through a 3-round Delphi survey involving axSpA patients and axSpA experts; iii) Consensus and voting by ASAS; iv) Endorsement by OMERACT. Two scenarios are considered based on the type of therapy investigated in the trial: symptom modifying therapies and disease modifying therapies. RESULTS The updated core outcome set for axSpA includes 7 mandatory domains for all trials (disease activity, pain, morning stiffness, fatigue, physical function, overall functioning and health, and adverse events including death). There are 3 additional domains (extra-musculoskeletal manifestations, peripheral manifestations and structural damage) that are mandatory for disease modifying therapies and important but optional for symptom modifying therapies. Finally, 3 other domains (spinal mobility, sleep, and work and employment) are defined as important but optional domains for all trials. CONCLUSION The ASAS-OMERACT core domain set for AS has been updated into the ASAS-OMERACT core domain set for axSpA. The next step is the selection of instruments for each domain.
Collapse
Affiliation(s)
- V Navarro-Compán
- Rheumatology Service, Hospital Universitario la Paz-IdiPaz, Madrid, Spain
| | - A Boel
- Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands
| | - A Boonen
- Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, the Netherlands and Care and Public Health Research Institute (CAPHRI), Maastricht University, the Netherlands
| | - P Mease
- Division of Rheumatology, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA
| | - R Landewé
- Department of rheumatology & clinical immunology, Amsterdam University Medical Center loc. amC, Amsterdam & Zuyderland MC
- loc. Heerlen, The Netherlands
| | - U Kiltz
- Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany
| | - M Dougados
- Université de Paris Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France
| | - X Baraliakos
- Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany
| | - W Bautista-Molano
- Rheumatology Department, University Hospital Fundación Santa Fe de Bogotá and School of Medicine Universidad El Bosque. Bogotá, Colombia
| | - H Carlier
- Global Clinical Development Immunology, S.A. Eli Lilly Benelux N.V., Brussels, Belgium
| | | | - H Dagfinrud
- Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
| | | | | | - L Fallon
- Inflammation and Immunology - Global Medical Affairs, Pfizer Inc, Kirkland, Quebec, Canada
| | - K Gaffney
- Rheumatology Department, Norfolk & Norwich University Hospitals NHS Foundation Trust, Norwich, UH
| | - M Garrido-Cumbrera
- Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain. Spanish Federation of Spondyloartrhtis Associations (CEADE), Madrid, Spain
| | - L S Gensler
- Division of Rheumatology, Department of Medicine, University of Calfornia, San Francisco, CA, USA
| | - N Haroon
- University of Toronto, Departement of Medicine, University Health Network, Schroder Artritis Institute, Toronto
| | - Y H Kwan
- Program in Health Systems and Services Research, Duke-NUS Medical School, Department of Pharmacy, National University of Singapore, Department of Rheumatology and Immunology, Singapore General Hospital
| | - P M Machado
- Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom; National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom
| | - W P Maksymowych
- Department of Medicine, University of Alberta, Edmonton, Canada
| | - D Poddubnyy
- Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - M Protopopov
- Department of Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Germany
| | - S Ramiro
- Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, Zuyderland Medical Center, Heerlen, the Netherlands
| | - B Shea
- Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, ON, Canada
| | - I H Song
- Immunology Clinical Development, 1 North Waukegan Road Building AP31-2, North Chicago, IL 60064, USA
| | - S van Weely
- Department of Orthopaedics, Rehabilitation and Physical Therapy, Leiden University Medical Center, Leiden, the Netherlands
| | - D van der Heijde
- Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands
| |
Collapse
|
2
|
Ogdie A, Harrison R, McLean R, Lin T, Lebwohl M, Strober B, Zhuo J, Patel V, Mease P. 301 Psoriatic arthritis risk in psoriasis patients in the Corrona® Psoriasis Registry. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Mease P, Okada M, Kishimoto M, Shuler C, Carlier H, Lin C, Mou J, Moriarty S, Lee C, Gladman D, Satler M. 397 Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.592] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
4
|
Huynh DH, Boyd TA, Etzel CJ, Cox V, Kremer J, Mease P, Kavanaugh A. Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis. RMD Open 2017; 3:e000395. [PMID: 28123783 PMCID: PMC5255890 DOI: 10.1136/rmdopen-2016-000395] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2016] [Accepted: 11/30/2016] [Indexed: 11/19/2022] Open
Abstract
Objective To determine the duration of clinical benefit among patients with psoriatic arthritis (PsA) discontinuing tumour necrosis factor inhibitor (TNFi) therapy while in low disease activity (LDA), and to identify patient characteristics associated with prolonged clinical benefit. Methods We performed an observational cohort study assessing patients with PsA from the Consortium of Rheumatology Researchers of North America (CORRONA) registry who had discontinued TNFi after achieving LDA, defined as clinical disease activity index (CDAI) score ≤10 and physician's global assessment (PGA) of skin psoriasis ≤20/100. Kaplan–Meier method was used to estimate the duration of clinical benefit. Results Of the 5945 patients with PsA in CORRONA, 302 patients had discontinued TNFi (n=325) while in LDA and had follow-up data available. At time of discontinuation, mean PsA duration was 9.8 years, mean CDAI was 3.9, and mean duration of TNFi use was 1.5 years; 52.6% of patients had discontinued their first TNFi. Median time to loss of benefit was 29.2 months. 179 (55.1%) patients had persistent benefit at their previous clinic visit. An increased risk of losing clinical benefit was seen among patients with higher disease activity at discontinuation (CDAI≥3.2 vs <3.2; HR 1.43 (p=0.32)) and among smokers (HR 1.78 (p=0.027)). Conclusions Patients with PsA who achieve LDA may maintain clinical benefit after discontinuation of TNFi therapy.
Collapse
Affiliation(s)
- D H Huynh
- Allergy and Rheumatology Clinic , La Jolla, California , USA
| | - T A Boyd
- Division of Rheumatology, Department of Medicine , Western University , London, Ontario , Canada
| | - C J Etzel
- Corrona LLC , Southborough, Massachusetts , USA
| | - V Cox
- Corrona LLC , Southborough, Massachusetts , USA
| | - J Kremer
- Corrona LLC , Southborough, Massachusetts , USA
| | - P Mease
- Swedish Medical Center and University of Washington , Seattle, Washington , USA
| | - A Kavanaugh
- Division of Rheumatology, Allergy and Immunology, University of California, San Diego, California, USA; School of Medicine, La Jolla, California, USA
| |
Collapse
|
5
|
Mease P, van der Heijde D, Ritchlin C, Cuchacovich R, Shuler C, Lin CY, Vangerow H, Samanta S, Lee C, Gladman D, Augendre-Ferrante B. Étude de phase 3 de l’ixékizumab versus adalimumab et placebo chez des patients atteints de rhumatisme psoriasique naïfs de DMARDS biologiques. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Kavanaugh A, Mease P, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Wang Z, Mpofu S. FRI0448 Secukinumab Provides Sustained Improvements in The Signs and Symptoms of Active Psoriatic Arthritis: 2-Year Efficacy and Safety Results from The Phase 3 Randomised, Double-Blind, Placebo-Controlled Trial, Future 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3565] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
7
|
Coates L, Mease P, Kirkham B, McLeod L, Mpofu S, Karyekar C, Gandhi K. FRI0463 Secukinumab Improves Minimal Disease Activity Response Rates in Patients with Active Psoriatic Arthritis: Data from The Randomized Phase 3 Study, Future 2. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3949] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
8
|
Baeten D, Mease P, Strand V, McInnes I, Thom H, Kanters S, Palaka E, Gandhi K, Richards H, Jugl S. SAT0390 Secukinumab for The Treatment of Ankylosing Spondylitis: Comparative Effectiveness Results versus Currently Licensed Biologics from A Network Meta-Analysis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
9
|
Doedens J, Jones W, Hill K, Mason M, Linsley P, Mease P, Dall'Era M, Aranow C, Martin R, Cohen S, Fleischmann R, Kivitz A, Burge D, Chaussabel D, Elkon K, Posada J, Gabel C. OP0186 Immune Complex Bound U1 and Y1 RNA Correlates with Interferon-Stimulated Gene Expression and Disease Activity: An Observational Study of Sysytemic Lupus Erythematosus Patients. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
10
|
Fleischmann R, Mease P, Schwartzman S, Hwang LJ, Soma K, Connell C, Takiya L, Bananis E. THU0200 Effect of Methotrexate Dose on The Efficacy of Tofacitinib: Treatment Outcomes from A Phase 3 Clinical Trial of Patients with Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
11
|
Mease P, Marzo-Ortega H, Poder A, Van den Bosch F, Wollenhaupt J, Lespessailles E, McIlraith M, Teng L, Hall S. THU0420 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in BASDAI in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
12
|
Mease P, Gottlieb A, Menter A, Ritchlin C, Kalia S, Kerdel F, Kafka S, Morgan J, Langholff W, Fakharzadeh S, Goyal K. THU0450 All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in The Psoriasis Longitudinal Assessment and Registry Study. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
13
|
Kirkham B, Mease P, McInnes I, Bhosekar V, Mpofu S, Gandhi K, Gaillez C. FRI0451 Secukinumab Provides Rapid and Sustained Reductions in Dactylitis and Enthesitis in Patients with Psoriatic Arthritis: Analysis of Data from The Phase 3 Randomised, Multicentre, Double-Blind, Placebo-Controlled Future 2 Study: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
14
|
Nash P, McInnes I, Mease P, Thom H, Cure S, Palaka E, Gandhi K, Mpofu S, Jugl S. THU0448 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab Up To 48 Weeks Using A Matching-Adjusted Indirect Comparison. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2049] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
15
|
Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczyński P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, Landewé R, de Longueville M, Hoepken B, Peterson L, van der Heijde D. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open 2015; 1:e000119. [PMID: 26509074 PMCID: PMC4612702 DOI: 10.1136/rmdopen-2015-000119] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Revised: 06/01/2015] [Accepted: 06/07/2015] [Indexed: 12/16/2022] Open
Abstract
Objective Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 24 weeks in patients with psoriatic arthritis (PsA), including patients with prior antitumour necrosis factor (TNF) therapy. We report efficacy and safety data from a 96-week data cut of RAPID-PsA. Methods RAPID-PsA was placebo-controlled to week 24, dose-blind to week 48 and open-label to week 216. We present efficacy data including American College of Rheumatology (ACR)/Psoriasis Area and Severity Index (PASI) responses, HAQ-DI, pain, minimal disease activity (MDA), modified total Sharp score (mTSS) and ACR responses in patients with/without prior anti-TNF exposure, in addition to safety data. Results Of 409 patients randomised, 273 received CZP from week 0. 54 (19.8%) CZP patients had prior anti-TNF exposure. Of patients randomised to CZP, 91% completed week 24, 87% week 48 and 80% week 96. ACR responses were maintained to week 96: 60% of patients achieved ACR20 at week 24, and 64% at week 96. Improvements were observed with both CZP dose regimens. ACR20 responses were similar in patients with (week 24: 59%; week 96: 63%) and without (week 24: 60%; week 96: 64%) prior anti-TNF exposure. Placebo patients switching to CZP displayed rapid clinical improvements, maintained to week 96. In patients with ≥3% baseline skin involvement (60.8% week 0 CZP patients), PASI responses were maintained to week 96. No progression of structural damage was observed over the 96-week period. In the Safety Set (n=393), adverse events occurred in 345 patients (87.8%) and serious adverse events in 67 (17.0%), including 6 fatal events. Conclusions CZP efficacy was maintained to week 96 with both dose regimens and in patients with/without prior anti-TNF exposure. The safety profile was in line with that previously reported from RAPID-PsA, with no new safety signals observed with increased exposure. Trial registration number NCT01087788.
Collapse
Affiliation(s)
- P Mease
- Swedish Medical Center and University of Washington , Seattle, Washington , USA
| | - A Deodhar
- Oregon Health & Science University , Portland, Oregon , USA
| | - R Fleischmann
- University of Texas SW Medical Center , Dallas, Texas , USA
| | | | - D Gladman
- Toronto Western Research Institute , Toronto , Canada
| | - P Leszczyński
- Poznan Medical University , Poznan , Poland ; Division of Rheumatology and Osteoporosis , Jozef Strus Hospital , Poznan , Poland
| | - P Vitek
- PV-MEDICAL, Revmavita Centre , Zlin , Czech Republic
| | - A Turkiewicz
- Rheumatology Associates Clinical Research Unit , Birmingham, Alabama , USA
| | - M Khraishi
- Department of Medicine , Memorial University of Newfoundland , St. John's , Canada
| | - O FitzGerald
- Department of Rheumatology , St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College , Dublin , Ireland
| | - R Landewé
- Academic Medical Center, Amsterdam and Atrium Medical Center , Heerlen , The Netherlands
| | | | | | - L Peterson
- UCB Pharma , Raleigh, North Carolina , USA
| | | |
Collapse
|
16
|
Kirkham B, McInnes I, Mease P, Kremer J, Kandala S, Pricop L, Mpofu S. THU0421 Secukinumab is Effective in Reducing Dactylitis and Enthesitis Using Multiple Measures in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 2). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2276] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
17
|
McInnes I, Mease P, Kirkham B, Kavanaugh A, Ritchlin C, Rahman P, van der Heijde D, Landewé R, Conaghan P, Gottlieb A, Richards H, Ligozio G, Pricop L, Mpofu S. THU0425 Secukinumab Improves Signs and Symptoms of Active Psoriatic Arthritis in a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using a Subcutaneous Dosing Regimen (Future 2). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2265] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
18
|
Mease P, Kavanaugh A, Coates L, McInnes I, Hojnik M, Zhang Y, Anderson J, Dorr A, Gladman D. THU0431 The Prediction and Benefits of Minimal Disease Activity in Patients with Psoriatic Arthritis in the Adept Trial. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1469] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
19
|
Gladman D, Kavanaugh A, Adebajo A, Gomez-Reino J, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, McIlraith M, Hu C, Edwards C, Birbara C, Mease P. OP0169 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3594] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
20
|
Lederman S, Clauw D, Gendreau J, Arnold L, Moldofsky H, Mease P, Daugherty B, Gendreau R. THU0325 TNX-102 SL for the Treatment of Fibromyalgia: Role of Nonrestorative Sleep on Pain Centralization. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
21
|
Mease P, Gladman D, Ritchlin C, Warren R, Rubant S, Li Y, Dorr A, Anderson J. AB0822 Therapeutic Response in Adalimumab-Treated Patients with Psoriatic Arthritis in Relation to Weight. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1339] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
22
|
Schaefer C, Adams E, Udall M, Masters E, Mann R, Daniel S, McElroy H, Cappelleri J, Clair A, Hopps M, Staud R, Mease P, Silverman S. THU0321 Multisite Prospective Observational Study of Fibromyalgia Patients in the Us. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
23
|
Mease P, McInnes I, Richards H, Pricop L, Widmer A, Mpofu S. SAT0579 Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials (Future 1 and Future 2). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
24
|
van der Heijde D, Landewé R, Mease P, McInnes I, Conaghan P, Pricop L, Ligozio G, Richards H, Mpofu S. THU0414 Secukinumab Inhibits Radiographic Progression in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 1). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1806] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
25
|
Kavanaugh A, Adebajo A, Gladman D, Gomez-Reino J, Hall S, Lespessailles E, Mease P, Schett G, Shah K, Hu C, Wollenhaupt J. THU0420 Long-Term (104-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomised, Controlled Trial and Open-Label Extension (Palace 1). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2907] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
26
|
Mease P, van der Heijde D, Mittal M, Joshi A, Xu Y, Pangan A, Song IH. AB1158 Quality of Life in Patients with Active Peripheral SPA is Similarly Impaired as in Other Rheumatic Diseases and Influenced by Disease Activity But not Disease Duration. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
27
|
Gottlieb A, McInnes I, Mease P, Rahman P, Kandala S, Patekar M, Mpofu S. THU0418 Secukinumab Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from the Phase 3 Future 2 Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2852] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
28
|
Mease P, Adebajo A, Gladman D, Gomez-Reino J, Hall S, Kavanaugh A, Lespessailles E, Schett G, Shah K, Teng L, Wollenhaupt J. THU0432 Long-Term (104-Week) Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled Trials. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3582] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
van den Bosch F, Mease P, Sieper J, Baeten D, Varothai N, Pangan A, Song IH. THU0240 Early Clinical Response is a Better Predictor of Long-Term Remission than Baseline Disease Characteristics Following Adalimumab Treatment in Peripheral Spondyloarthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Mease P, Genovese M, Greenwald M, Ritchlin C, Beaulieu A, Deodhar A, Newmark R, Feng J, Erondu N, Nirula A. OP0175 Two-Year Clinical Response to Brodalumab, An Anti-IL-17 Receptor Antibody, in Patients with Psoriatic Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3489] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
31
|
Gladman D, Mease P, Smolen J, Weinman J, Kalus S, Dorr A, Hojnik M, Nurwakagari P, Selenko-Gebauer N. SAT0566 Impact of Disease Management by Rheumatologists and Dermatologists on Patients' Attitude Toward Medication in Psoriatic Arthritis: Results from the Global Align Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S, Kaplan I, Krishnaswami S, Luo Z, Bradley J, Firestein GS. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2014; 74:1311-6. [PMID: 25398374 PMCID: PMC4431345 DOI: 10.1136/annrheumdis-2014-206028] [Citation(s) in RCA: 183] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2014] [Accepted: 10/24/2014] [Indexed: 12/29/2022]
Abstract
Objective Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The pathways affected by tofacitinib and the effects on gene expression in situ are unknown. Therefore, tofacitinib effects on synovial pathobiology were investigated. Methods A randomised, double-blind, phase II serial synovial biopsy study (A3921073; NCT00976599) in patients with RA with an inadequate methotrexate response. Patients on background methotrexate received tofacitinib 10 mg twice daily or placebo for 28 days. Synovial biopsies were performed on Days -7 and 28 and analysed by immunoassay or quantitative PCR. Clinical response was determined by disease activity score and European League Against Rheumatism (EULAR) response on Day 28 in A3921073, and at Month 3 in a long-term extension study (A3921024; NCT00413699). Results Tofacitinib exposure led to EULAR moderate to good responses (11/14 patients), while placebo was ineffective (1/14 patients) on Day 28. Tofacitinib treatment significantly reduced synovial mRNA expression of matrix metalloproteinase (MMP)-1 and MMP-3 (p<0.05) and chemokines CCL2, CXCL10 and CXCL13 (p<0.05). No overall changes were observed in synovial inflammation score or the presence of T cells, B cells or macrophages. Changes in synovial phosphorylation of signal transducer and activator of transcription 1 (STAT1) and STAT3 strongly correlated with 4-month clinical responses (p<0.002). Tofacitinib significantly decreased plasma CXCL10 (p<0.005) at Day 28 compared with placebo. Conclusions Tofacitinib reduces metalloproteinase and interferon-regulated gene expression in rheumatoid synovium, and clinical improvement correlates with reductions in STAT1 and STAT3 phosphorylation. JAK1-mediated interferon and interleukin-6 signalling likely play a key role in the synovial response. Trial registration number NCT00976599.
Collapse
Affiliation(s)
- D L Boyle
- University of California, San Diego School of Medicine, San Diego, California, USA
| | - K Soma
- Pfizer Inc, Groton, Connecticut, USA
| | - J Hodge
- Pfizer Inc, New York, New York, USA
| | - A Kavanaugh
- University of California, San Diego School of Medicine, San Diego, California, USA
| | - D Mandel
- Office of David R Mandel MD, Inc., Mayfield Village, Ohio, USA
| | - P Mease
- Swedish Medical Center and University of Washington, Seattle, Washington, USA
| | - R Shurmur
- Bronson Internal Medicine and Rheumatology, Battle Creek, Michigan, USA
| | - A K Singhal
- Southwest Rheumatology Research LLC, Dallas, Texas, USA
| | - N Wei
- Arthritis Treatment Center, Frederick, Maryland, USA
| | - S Rosengren
- University of California, San Diego School of Medicine, San Diego, California, USA
| | - I Kaplan
- Pfizer Inc, Groton, Connecticut, USA
| | | | - Z Luo
- Pfizer Inc, Shanghai, China
| | - J Bradley
- Pfizer Inc, Groton, Connecticut, USA
| | - G S Firestein
- University of California, San Diego School of Medicine, San Diego, California, USA
| |
Collapse
|
33
|
Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Ann Rheum Dis 2014; 74:44-51. [PMID: 24942382 PMCID: PMC4283690 DOI: 10.1136/annrheumdis-2014-205198] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVES To evaluate the effect of certolizumab pegol (CZP) on productivity outside and within the home, and on participation in family, social and leisure activities in adult patients with psoriatic arthritis (PsA). METHODS RAPID-PsA (NCT01087788) is a phase 3, double-blind, placebo-controlled trial. 409 patients with active PsA were randomised 1:1:1 to placebo, CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W). The arthritis-specific Work Productivity Survey (WPS) assessed the impact of PsA on paid work and household productivity, and participation in social activities during the preceding month. WPS responses were compared between treatment arms using a non-parametric bootstrap-t method. RESULTS At baseline, 56.6%, 60.1% and 61.5% of placebo, CZP 200 mg Q2W and CZP 400 mg Q4W patients were employed. By week 24, employed CZP patients reported an average of 1.0-1.8 and 3.0-3.9 fewer days of absenteeism and presenteeism, respectively, per month compared with 1.0 and 0.3 fewer days for placebo patients (p<0.05). Within the home, by week 24, CZP patients reported an average of 3.0-3.5 household work days gained per month versus 1.0 day for placebo (p<0.05). CZP patients also reported fewer days with reduced household productivity or days lost for participation in family, social and leisure activities. Improvements with CZP were seen as early as week 4 and continued to week 24. CONCLUSIONS CZP treatment significantly improved productivity at paid work and within the home, and resulted in greater participation in social activities for PsA patients. TRIAL REGISTRATION NUMBER NCT01087788.
Collapse
Affiliation(s)
- A Kavanaugh
- Division of Rheumatology, Allergy and Immunology, UCSD, San Diego, California, USA
| | - D Gladman
- Division of Health Care & Outcomes Research, Toronto Western Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada
| | - D van der Heijde
- Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands
| | | | - P Mease
- Swedish Medical Center and University of Washington, Seattle, Washington, USA
| |
Collapse
|
34
|
Mease P, Van den Bosch F, Baeten D, Sieper J, Song IH, Karunaratne P, Pangan A. FRI0128 Utility of Enthesitis Assessments in Peripheral Spondyloarthritis – Data from the Ability-2 Trial: Table 1. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
35
|
Weinblatt M, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Zilberstein M, Xing J, Emery P. SAT0244 A Phase Iib Study of the Efficacy and Safety of Subcutaneous Clazakizumab (ANTI-IL-6 Monoclonal Antibody) with or without Methotrexate in Adults with Moderate-To-Severe Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.3754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
Mease P, Karunaratne P, Kupper H, Hojnik M, Dorr A, McInnes I. AB0757 Achievement of A Combined Clinical and Radiographic Endpoint in Patients with Psoriatic Arthritis in the ADEPT Trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
37
|
Schett G, Mease P, Gladman D, Kavanaugh A, Adebajo A, Gomez-Reino J, Wollenhaupt J, Cutolo M, Lespessailles E, Hu C, Stevens R, Edwards C, Birbara C. AB0746 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1773] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
Kavanaugh A, McInnes I, Mease P, Krueger G, Gladman D, Xu S, Tang L, Van Beneden K. OP0080 Impact of Persistent Minimal Disease Activity on Long-Term Outcomes in Psoriatic Arthritis: Results from 5 Years of the Long Term Extension of A Randomized, Placebo-Controlled, Study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2254] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
39
|
Van den Bosch F, Mease P, Sieper J, Baeten D, Karunaratne P, Song IH, Pangan A. SAT0342 Arthritis and Enthesitis Remission during Adalimumab Treatment in Peripheral Spondyloarthritis: Year-2 Results from Ability-2:. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Ramiro S, Turina M, Baeten D, Mease P, Paramarta J, Song IH, Pangan A, Landewe R. FRI0138 A Psychometric Analysis of Outcome Measures in Trials of Peripheral Spondyloarthritis: Table 1. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
41
|
Kavanaugh A, Cutolo M, Mease P, Gladman D, Adebajo A, Gomez-Reino J, Wollenhaupt J, Schett G, Lespessailles E, Hu C, Stevens R, Edwards C, Birbara C. OP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1827] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
42
|
Mease P, Gladman D, Kavanaugh A, Adebajo A, Gomez-Reino J, Wollenhaupt J, Schett G, Shah K, Hu C, Stevens R, Edwards C, Birbara C. AB0758 Change in Weight from Baseline during the Palace Clinical Trial Program with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2391] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Favarato MH, Mease P, Gonçalves CR, Gonçalves Saad C, Sampaio-Barros PD, Goldenstein-Schainberg C. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis. Clin Exp Rheumatol 2014; 32:182-187. [PMID: 24480317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2013] [Accepted: 11/12/2013] [Indexed: 06/03/2023]
Abstract
OBJECTIVES New evidence has lightened the linkage between psoriatic arthritis (PsA) and the development of atherosclerosis and cardiovascular disease (CVD). We aimed to describe the prevalence of cardiovascular events and associated risk factors among patients with PsA. METHODS Retrospective evaluation of medical records from consecutive PsA patients who fulfilled the CASPAR criteria for PsA attending a specialised spondyloarthritis clinic at a single referral centre. CVD was defined based on the occurrence of coronary artery disease (CAD) or cerebrovascular ischaemic disease events. RESULTS We evaluated 158 PsA patients, 48.7% females and 51.3% males, aged 53.7±13.9 yrs. Mean PsA duration was 13.7±8.9 yrs and polyarticular subtype affected 66 (42%) patients. According to drug therapy, 85 (54%) were using NSAIDs and 21 (13%) low-dose prednisone; 32 (20%) were on anti-TNF agents, 94 (60%) metothrexate, 18 (11%) leflunomide, 13 (8%) sulfasalazine, 5 (3%) other immunossupressors and 4 (2.5%) were on chloroquine. Over half patients (87, 55%) had arterial hypertension (AH); 51 (32%) had dyslipidaemia (DLP), 38 (29%) hypertriglyceridemia and 36 (23%) diabetes mellitus (DM). Lipid profile was similar for both genders with mean total cholesterol= 186.5±38.6mg/dl, LDL=112.3±30.6 mg/dl, HDL= 47.89±14.6 and triglycerides= 127.4± 65.6 mg/dl. Of note, 14% PsA patients have had CVD, namely cerebrovascular or coronary heart disease. Sex, age, disease duration, joint involvement subtype, disease activity, CRP and lipid levels were similar among patients with and without CVD. The prevalence of AH (95% vs. 45%, p<0.001), DLP (75% vs. 27.7%, p<0.001) and DM (60% vs. 19%, p<0.001) were significantly greater in PsA patients who have had CVD compared to those without CVD, conferring an odds ratio of 21.0 for AH and of 5.4 for DM. CONCLUSIONS The high prevalence of CVD in PsA patients is influenced by increased AH and DM. Hence early recognition and specific treatment is mandatory in order to reduce the risk for CVD, avoiding early morbidity and mortality.
Collapse
Affiliation(s)
- M H Favarato
- Faculdade de Medicina da Universidade de São Paulo e Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil.
| | | | | | | | | | | |
Collapse
|
44
|
Mease P, Sieper J, van den Bosch F, Rahman P, Obermeyer K, Pangan A. THU0280 Efficacy and safety of adalimumab in patients with peripheral spondyloarthritis: Results from a phase 3 study:. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.2245] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
45
|
Coates L, Fitzgerald O, Gladman D, McHugh N, Mease P, Strand V, Helliwell P. SAT0305 MDA criteria for PSA show good correlation with physician and patient opinions and with proposed composite measures. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.3252] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
46
|
Smolen JS, Braun J, Dougados M, Emery P, FitzGerald O, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Schoels M, Sieper J, de Wit M, van der Heijde D. OP0110 Treat-To-Target Recommendations for Spondyloarthritis, Including Ankylosing Spondylitis and Psoriatic Arthritis: A Consensus of an International Task Force. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.315] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
47
|
Mease P, Collier D, Saunders K, Grant S, Bitman B, Chaudhari M, Greenberg J. SAT0263 Biologic Therapy, Time to Low Disease Activity, and Effect of Mono Vs. Background Oral Dmard Therapy Among Psoriatic Arthritis Patients in a US Registry. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.1988] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
48
|
Schoels MM, Braun J, Dougados M, Emery P, Fitzgerald O, Kavanaugh A, Kvien TK, Landewé R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Sieper J, Smolen JS, Wit MD, van der Heijde D. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis 2014; 73:238-42. [PMID: 23740234 PMCID: PMC3888585 DOI: 10.1136/annrheumdis-2013-203860] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/15/2013] [Indexed: 12/31/2022]
Abstract
BACKGROUND Current recommendations for the management of axial spondyloarthritis (SpA) and psoriatic arthritis are to monitor disease activity and adjust therapy accordingly. However, treatment targets and timeframes of change have not been defined. An international expert panel has been convened to develop 'treat-to-target' recommendations, based on published evidence and expert opinion. OBJECTIVE To review evidence on targeted treatment for axial and peripheral SpA, as well as for psoriatic skin disease. METHODS We performed a systematic literature search covering Medline, Embase and Cochrane, conference abstracts and studies in http://www.clinicaltrials.gov. RESULTS Randomised comparisons of targeted versus routine treatment are lacking. Some studies implemented treatment targets before escalating therapy: in ankylosing spondylitis, most trials used a decrease in Bath Ankylosing Spondylitis Disease Activity Index; in psoriatic arthritis, protocols primarily considered a reduction in swollen and tender joints; in psoriasis, the Modified Psoriasis Severity Score and the Psoriasis Area and Severity Index were used. Complementary evidence correlating these factors with function and radiographic damage at follow-up is sparse and equivocal. CONCLUSIONS There is a need for randomised trials that investigate the value of treat-to-target recommendations in SpA and psoriasis. Several trials have used thresholds of disease activity measures to guide treatment decisions. However, evidence on the effect of these data on long-term outcome is scarce. The search data informed the expert committee regarding the formulation of recommendations and a research agenda.
Collapse
Affiliation(s)
- M M Schoels
- 2nd Department of Internal Medicine, Center for Rheumatic Diseases, Hietzing Hospital, , Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Coates L, Fitzgerald O, Gladman D, McHugh N, Mease P, Strand V, Helliwell P. SAT0291 Reduced joint counts misclassify PSA patients with oligoarthritis and miss significant active disease. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.3238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
50
|
Mease P, van Vollenhoven R, Durez P, Sheeran T, Dougados M, Gόmez-Reino J, Tyson N, Mehbob A, Lehane P. FRI0201 Analysis of infection risk in patients with limited return of peripheral B cells after a period of 2 years or more following any rituximab treatment course in RA clinical trials:. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|